Despite approval, new MS drug still unavailable

A newly approved treatment for multiple sclerosis will remain unavailable to Australian patients for the foreseeable future, its manufacturers say.

The drug alemtuzumab, developed and marketed by Genzyme as Lemtrada, received TGA approval last December for the treatment of relapsing multiple sclerosis in patients with active disease.

But on Monday a spokesman for Genzyme’s parent company Sanofi said there was no timeline for when the drug would be marketed in Australia, even though its approval was “an important step in making this treatment available”.